Does the media prefer SRZN or RIGL?

In the previous week, Surrozen had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 4 mentions for Surrozen and 3 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.95 beat Surrozen's score of 0.47 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rigel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is CLYM or SRZN more profitable?

Climb Bio has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.79% -30.79% Surrozen -2,885.33% N/A -93.62%

Does the media prefer CLYM or SRZN?

In the previous week, Climb Bio had 5 more articles in the media than Surrozen. MarketBeat recorded 9 mentions for Climb Bio and 4 mentions for Surrozen. Climb Bio's average media sentiment score of 0.95 beat Surrozen's score of 0.47 indicating that Climb Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Surrozen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SRZN or DBVT more profitable?

Surrozen has a net margin of -2,885.33% compared to DBV Technologies' net margin of -3,506.53%. Surrozen's return on equity of 0.00% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -2,885.33% N/A -93.62% DBV Technologies -3,506.53% -119.33% -84.43%

Does the media prefer SRZN or DBVT?

In the previous week, Surrozen had 1 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for Surrozen and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.07 beat Surrozen's score of 0.47 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DBV Technologies 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANNX or SRZN more profitable?

Annexon has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Surrozen -2,885.33% N/A -93.62%

Does the media favor ANNX or SRZN?

In the previous week, Annexon and Annexon both had 4 articles in the media. Annexon's average media sentiment score of 1.07 beat Surrozen's score of 0.47 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Surrozen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Surrozen (SRZN) Competitors

$17.84 -1.16 (-6.11%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$17.89 +0.05 (+0.25%)

As of 09/14/2026 07:30 PM Eastern

Compare

SRZN vs. RIGL, CLYM, DBVT, ANNX, and SLN

Should you buy Surrozen stock or one of its competitors? Surrozen's main competitors and comparable companies include Rigel Pharmaceuticals (RIGL), Climb Bio (CLYM), DBV Technologies (DBVT), Annexon (ANNX), and Silence Therapeutics (SLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Surrozen compare to Rigel Pharmaceuticals?

Surrozen (NASDAQ:SRZN) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

In the previous week, Surrozen had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 4 mentions for Surrozen and 3 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.95 beat Surrozen's score of 0.47 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Surrozen presently has a consensus target price of $45.00, suggesting a potential upside of 152.24%. Rigel Pharmaceuticals has a consensus target price of $59.00, suggesting a potential upside of 30.10%. Given Surrozen's stronger consensus rating and higher possible upside, analysts clearly believe Surrozen is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$11.51M	17.99	-$242.03M	-$40.55	N/A
Rigel Pharmaceuticals	$276.79M	3.03	$367.02M	$16.32	2.78

Surrozen has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

66.6% of Surrozen shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Surrozen's net margin of -2,885.33%. Rigel Pharmaceuticals' return on equity of 22.95% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Summary

Rigel Pharmaceuticals beats Surrozen on 9 of the 16 factors compared between the two stocks.

How does Surrozen compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Climb Bio has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.79%	-30.79%
Surrozen	-2,885.33%	N/A	-93.62%

Climb Bio currently has a consensus target price of $26.92, suggesting a potential upside of 84.91%. Surrozen has a consensus target price of $45.00, suggesting a potential upside of 152.24%. Given Surrozen's higher possible upside, analysts plainly believe Surrozen is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 2.6% of Climb Bio shares are held by insiders. Comparatively, 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Climb Bio has higher earnings, but lower revenue than Surrozen. Climb Bio is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
Surrozen	$11.51M	17.99	-$242.03M	-$40.55	N/A

Climb Bio has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

In the previous week, Climb Bio had 5 more articles in the media than Surrozen. MarketBeat recorded 9 mentions for Climb Bio and 4 mentions for Surrozen. Climb Bio's average media sentiment score of 0.95 beat Surrozen's score of 0.47 indicating that Climb Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Surrozen	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Climb Bio beats Surrozen on 10 of the 16 factors compared between the two stocks.

How does Surrozen compare to DBV Technologies?

Surrozen (NASDAQ:SRZN) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Surrozen currently has a consensus price target of $45.00, suggesting a potential upside of 152.24%. DBV Technologies has a consensus price target of $48.50, suggesting a potential upside of 292.71%. Given DBV Technologies' higher possible upside, analysts clearly believe DBV Technologies is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Surrozen has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, suggesting that its stock price is 195% less volatile than the broader market.

Surrozen has a net margin of -2,885.33% compared to DBV Technologies' net margin of -3,506.53%. Surrozen's return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

66.6% of Surrozen shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 31.7% of Surrozen shares are held by insiders. Comparatively, 1.1% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

DBV Technologies has lower revenue, but higher earnings than Surrozen. DBV Technologies is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$11.51M	17.99	-$242.03M	-$40.55	N/A
DBV Technologies	$5.64M	137.69	-$146.95M	-$3.51	N/A

In the previous week, Surrozen had 1 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for Surrozen and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.07 beat Surrozen's score of 0.47 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DBV Technologies	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Surrozen beats DBV Technologies on 9 of the 17 factors compared between the two stocks.

How does Surrozen compare to Annexon?

Annexon (NASDAQ:ANNX) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Annexon has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Surrozen	-2,885.33%	N/A	-93.62%

Annexon has higher earnings, but lower revenue than Surrozen. Annexon is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Surrozen	$11.51M	17.99	-$242.03M	-$40.55	N/A

66.6% of Surrozen shares are held by institutional investors. 10.3% of Annexon shares are held by company insiders. Comparatively, 31.7% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Annexon currently has a consensus target price of $15.14, indicating a potential upside of 283.36%. Surrozen has a consensus target price of $45.00, indicating a potential upside of 152.24%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Annexon and Annexon both had 4 articles in the media. Annexon's average media sentiment score of 1.07 beat Surrozen's score of 0.47 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Surrozen	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Annexon has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Summary

Annexon beats Surrozen on 8 of the 15 factors compared between the two stocks.

How does Surrozen compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Surrozen has a net margin of -2,885.33% compared to Silence Therapeutics' net margin of -8,943.86%. Surrozen's return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Surrozen	-2,885.33%	N/A	-93.62%

Silence Therapeutics has higher earnings, but lower revenue than Surrozen. Silence Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$615K	1,278.58	-$88.61M	-$1.28	N/A
Surrozen	$11.51M	17.99	-$242.03M	-$40.55	N/A

In the previous week, Surrozen had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 4 mentions for Surrozen and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.87 beat Surrozen's score of 0.47 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silence Therapeutics	Very Positive
Surrozen	Neutral

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Silence Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Silence Therapeutics presently has a consensus price target of $53.50, suggesting a potential upside of 309.65%. Surrozen has a consensus price target of $45.00, suggesting a potential upside of 152.24%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Silence Therapeutics is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Silence Therapeutics beats Surrozen on 9 of the 15 factors compared between the two stocks.

Get Surrozen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRZN vs. The Competition

Export

Metric	Surrozen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$220.59M	$3.86B	$7.16B	$14.29B
Dividend Yield	N/A	3.66%	2.57%	11.70%
P/E Ratio	-0.44	14.33	273.30	25.37
Price / Sales	17.99	1,514.01	666.61	88.28
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	-0.93	15.17	10.39	6.24
Net Income	-$242.03M	-$22.78M	$3.49B	$358.08M
7 Day Performance	-13.73%	-0.75%	-1.12%	-0.70%
1 Month Performance	-25.54%	2.15%	0.59%	-2.76%
1 Year Performance	53.13%	41.94%	20.20%	6.72%

Surrozen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRZN Surrozen	2.6481 of 5 stars	$17.84 -6.1%	$45.00 +152.2%	+54.2%	$220.59M	$11.51M	N/A	44
RIGL Rigel Pharmaceuticals	4.5742 of 5 stars	$47.24 -0.3%	$59.00 +24.9%	+19.5%	$872.92M	$276.79M	2.89	160
CLYM Climb Bio	3.3353 of 5 stars	$15.16 -4.7%	$26.92 +77.7%	+547.1%	$870.79M	N/A	N/A	9
DBVT DBV Technologies	3.4725 of 5 stars	$13.45 +1.4%	$48.50 +260.6%	+25.1%	$845.74M	$5.64M	N/A	80	Positive News Gap Up
ANNX Annexon	2.8323 of 5 stars	$4.47 -4.4%	$15.14 +239.1%	+63.2%	$844.57M	N/A	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRZN) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surrozen (SRZN) Competitors

SRZN vs. RIGL, CLYM, DBVT, ANNX, and SLN

How does Surrozen compare to Rigel Pharmaceuticals?

Summary

How does Surrozen compare to Climb Bio?

Summary

How does Surrozen compare to DBV Technologies?

Summary

How does Surrozen compare to Annexon?

Summary

How does Surrozen compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Surrozen (SRZN) Competitors

SRZN vs. RIGL, CLYM, DBVT, ANNX, and SLN

How does Surrozen compare to Rigel Pharmaceuticals?

Does the media prefer SRZN or RIGL?

Do analysts recommend SRZN or RIGL?

Which has stronger earnings and valuation, SRZN or RIGL?

Which has more volatility and risk, SRZN or RIGL?

Do insiders & institutionals hold more shares of SRZN or RIGL?

Is SRZN or RIGL more profitable?

Summary

How does Surrozen compare to Climb Bio?

Is CLYM or SRZN more profitable?

Do analysts rate CLYM or SRZN?

Do institutionals and insiders hold more shares of CLYM or SRZN?

Which has stronger valuation and earnings, CLYM or SRZN?

Which has more volatility & risk, CLYM or SRZN?

Does the media prefer CLYM or SRZN?

Summary

How does Surrozen compare to DBV Technologies?

Do analysts recommend SRZN or DBVT?

Which has more risk and volatility, SRZN or DBVT?

Is SRZN or DBVT more profitable?

Do insiders and institutionals hold more shares of SRZN or DBVT?

Which has preferable valuation and earnings, SRZN or DBVT?

Does the media prefer SRZN or DBVT?

Summary

How does Surrozen compare to Annexon?

Is ANNX or SRZN more profitable?

Which has stronger valuation & earnings, ANNX or SRZN?

Do institutionals & insiders believe in ANNX or SRZN?

Do analysts recommend ANNX or SRZN?

Does the media favor ANNX or SRZN?

Which has more volatility and risk, ANNX or SRZN?

Summary

How does Surrozen compare to Silence Therapeutics?

Is SLN or SRZN more profitable?

Which has higher earnings & valuation, SLN or SRZN?

Does the media favor SLN or SRZN?

Do insiders & institutionals hold more shares of SLN or SRZN?

Which has more risk & volatility, SLN or SRZN?

Do analysts rate SLN or SRZN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools